Fresenius Medical Care (FMS) Stock Analysis & Forecast

Nov 13 close

$22.03+0.43 (+2.0%)

Gekko Brief

Nov 9 close

Fresenius Medical Care closed at $22.95 on 9 November 2026, -1.9% on the day. The price sits between the 50-day ($22.33) and 200-day ($22.91) moving averages, inside a 52-week range of $20.02 to $26.42. The GekkoIndex reads 54, in the Neutral zone, down 0.9 points over five sessions. Gekko Fair Value is $38.43, so the price is 40.3% below it.

The next earnings report is due on 23 February 2027, 100 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 6.1% across the report. Seasonally, the next 20 trading days from this point averaged +5.3% over the last 5 years, rising in 3 of them.

2 firms rate the stock: 0 buy, 1 hold and 1 sell, with a consensus target of $23.39. A typical daily move is about 2.5%, and a typical 20-day move about 6.4%. On the swing-trade checklist, 3 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 9, 2026 close.

Fresenius Medical Care price vs fair value

▲$36.76$22.03Nov ’25May ’26Nov ’26
Close $22.03200-day averageGekko Fair Value $36.76

Fresenius Medical Care quick facts

Market cap
$11.92B
P/E ratio
12.8
Forward P/E
9.7
EPS, TTM
$1.73
Revenue, TTM
$19.48B
Profit margin
4.2%
Dividend yield
4.04%
Beta
0.79
Volume
1.33M avg 1.74M
1-year return
−8.0%
Typical daily move
±2.9%
Typical 20-day move
±6.4%
50-day average
$22.29
200-day average
$22.90
Next earnings
Feb 23 before open
Shares outstanding
519.0M
52-week range
$20.02$26.42

Fresenius Medical Care swing-trade checklist

Fresenius Medical Care scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive0 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $22.03 is below the 50-day ($22.29) and 200-day ($22.90) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    61.8, Accumulation

    Reading 61.8 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    40.1% below

    Price is 40.1% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +4.1% on average

    From this point in the calendar, the next 20 trading days averaged +4.1% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Fresenius Medical Care stock chart and price history

Fresenius Medical Care closed at $22.03 on Nov 13, 2026, −8.0% over the past year, inside a 52-week range of $20.02 to $26.42.

Close50-day average200-day averageVolume
Fresenius Medical Care share price, past year, with 50-day and 200-day moving averages and volume$20$24$26DecJan 2026FebMarAprMayJunJulAugSepOctNov22.03

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−0.5%
3 months
−6.3%
6 months
+2.0%
1 year
−8.0%
The full FMS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open FMS in Gekko

Follow Fresenius Medical Care through every session

Put FMS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track FMS in GekkoFree for 7 days. No credit card required.

About Fresenius Medical Care

Fresenius Medical Care works in kidney care, running clinics where people receive dialysis treatment along with related lab and diagnostic work. For patients who dialyze at home, it supplies the machines, trains them on use, and stays involved through medical oversight and by arranging delivery of supplies. In the United States it also partners with hospitals to treat inpatients dealing with acute kidney failure or end-stage renal disease.

On the product side, the company designs and builds dialysis equipment such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, solution concentrates, bloodlines, and water treatment systems, alongside renal drugs. It also makes devices unrelated to dialysis, including tools for acute cardiopulmonary support and apheresis. A separate pharmaceutical arm sources and develops specialized medicines for kidney patients, which are shipped both to people's homes and to treatment centers. The company additionally offers vascular, cardiovascular, and endovascular care, runs ambulatory surgery centers for vascular work, and supplies physician staffing in nephrology and cardiology. Its buyers include hospitals, dialysis clinics, and specialty centers, served through in-house sales staff as well as outside distributors, dealers, and agents.

The company traces back to 1996 and is headquartered in Bad Homburg, Germany, with operations spanning Germany, North America, and dozens of other countries. Its shares trade under the ticker FMS.

Sector
Health services
Website
freseniusmedicalcare.com

Fresenius Medical Care GekkoIndex: the smart money zone

Fresenius Medical Care’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.8, in the Accumulation zone, up 9.9 points over five sessions.

010061.8Accumulation

Up 9.9 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying46+1.2%+2.4%+3.0%+3.2%
Accumulation (current zone)204+0.5%+1.0%+2.4%+4.1%
Neutral3720.0%0.0%−0.1%+0.3%
Distribution33−0.6%−1.5%−1.7%−5.0%
Selling0Not available

Average FMS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the FMS price, zone by zone.Track FMS in Gekko

Is Fresenius Medical Care stock overvalued? Gekko Fair Value

Fresenius Medical Care trades 40.1% below Gekko Fair Value of $36.76, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Fresenius Medical Care shares are worth, recalculated every trading day.

$36.76

Gekko Fair Value, Nov 14, 2026

40.1% Undervalued

At the end of Aug 2026 the price was 9.5% below the estimate.

Gekko Fair ValueShare price, month end
$37$22Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open FMS in Gekko

Fresenius Medical Care insider and Congress trading

No open-market insider purchases were filed for Fresenius Medical Care, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for FMS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every FMS insider filing, plotted on the chart in Gekko.Open FMS in Gekko

Congress trades last 90 days

No trades in FMS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for FMS, plotted on the chart in Gekko.Open FMS in Gekko

Fresenius Medical Care earnings: next date and track record

Fresenius Medical Care reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±6.1%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+1.1%Feb ’25+10.2%May ’25−5.7%Aug ’25−8.0%Nov ’25−7.9%Feb ’26−7.2%May ’26−6.4%Aug ’26+2.6%Nov ’26

Last earnings call, Nov 3, 2026 AI summary

What they said
Fresenius Medical Care reported broadly stable Q3 2026 revenue and earnings despite TDAPA reimbursement headwinds. New CEO Shervin Korangy joined three weeks prior, emphasizing long-term profitable growth in kidney care. The 5008X HV-HDF machine rollout converted 14% of clinics (348 clinics, ~9,000 machines) by end of September, tracking toward 20% install base conversion by year-end. Approximately 300,000 HV-HDF treatments were performed in the first nine months.
Guidance
Management targets converting 20% of install base to HV-HDF by year-end 2026. New CEO plans to roll out 2027 strategic planning in due course, emphasizing long-term profitable growth while delivering near-term milestones to build shareholder confidence.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 3, 2026$0.64
est $0.65
−1.7%$5.53B
est $5.52B
0.0%+2.6%
Aug 3, 2026$0.66
est $0.62
+7.1%$5.60B
est $5.48B
+2.2%−6.4%
May 5, 2026$0.46
est $0.53
−13.6%$5.40B
est $5.41B
−0.1%−7.2%
Feb 24, 2026$0.83
est $0.65
+28.3%$5.97B
est $5.67B
+5.3%−7.9%
Nov 4, 2025$0.64
est $0.59
+8.5%$5.72B
est $4.80B
+19.2%−8.0%
Aug 5, 2025$0.52
est $0.50
+4.0%$5.64B
est $4.98B
+13.4%−5.7%
May 6, 2025$0.44
est $0.43
+2.3%$5.35B
est $5.06B
+5.8%+10.2%
Feb 25, 2025$0.46
est $0.40
+13.6%$5.27B
est $4.66B
+13.1%+1.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Fresenius Medical Care stock forecast and analyst price targets

Analysts’ average 12-month price target for Fresenius Medical Care is $22.97, +4.3% from the last close, from 2 firms rating the stock in the last 90 days.

$22.97consensus 12-month target, +4.3% from the last close
Buy0
Hold1
Sell1

Each firm’s latest rating in the last 90 days: 2 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 4Bank of America SecuritiesSell, maintained——
Oct 12Truist FinancialHold, maintained$24+8.9%
Aug 26Truist FinancialHold, maintained$25+13.5%
+2.4%average 20-day move after past Accumulation readings
+4.1%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Fresenius Medical Care seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Fresenius Medical Care averaged +4.1% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−7.0%2021+5.1%2022+8.7%2023+10.9%2024+1.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.5%3 of 5
Next 10 trading days+0.9%4 of 5
Next 15 trading days+2.5%3 of 5
Next 20 trading days+4.1%4 of 5
Next 30 trading days+3.9%4 of 5

For scale, FMS’s typical 20-trading-day move in either direction is about 6.4%.

Fresenius Medical Care market cap and key statistics

Fresenius Medical Care’s market cap is $11.92B, with a P/E ratio of 12.8 and revenue of $19.48B over the last twelve months.

Valuation

Market cap
$11.92B
P/E ratio
12.8
Forward P/E
9.7
EPS, TTM
$1.73
Gekko Fair Value
$36.76

Trading

Volume
1.33M
Avg volume, 20 days
1.74M
52-week high
$26.42
52-week low
$20.02
Shares outstanding
519.0M

Financials

Revenue, TTM
$19.48B
Profit margin
4.2%
Return on equity
7.8%
Quarterly earnings growth, YoY
−35.4%

Risk and income

Beta
0.79
Typical daily move
±2.9%
Typical 20-day move
±6.4%
Dividend yield
4.04%

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health services

Fresenius Medical Care stock FAQ

What is Fresenius Medical Care’s market cap?

Fresenius Medical Care’s market cap is $11.92B at the Nov 13, 2026 close of $22.03, with 519.0M shares outstanding. The shares trade on a P/E ratio of 12.8.

What is the Fresenius Medical Care stock forecast?

The consensus analyst 12-month price target for Fresenius Medical Care is $22.97, +4.3% from the last close. Of the 2 firms that rated the stock in the last 90 days, 0 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Fresenius Medical Care stock overvalued or undervalued?

On Gekko’s estimate Fresenius Medical Care is undervalued: the Nov 13, 2026 close of $22.03 is 40.1% below Gekko Fair Value of $36.76. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Fresenius Medical Care report earnings next?

Fresenius Medical Care is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.56 per share on revenue of $5.60B. Fresenius Medical Care beat the earnings estimate in 6 of its last 8 reports, moving 6.1% on average across the report.

What is Fresenius Medical Care’s 52-week high and low?

Fresenius Medical Care’s 52-week high is $26.42 and its 52-week low is $20.02; it closed at $22.03 on Nov 13, 2026, −8.0% over the past year. Over the last five years the shares peaked at $35.04 on Feb 3, 2022.

Is Fresenius Medical Care stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Fresenius Medical Care the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.